Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Itacitinib in Treating Patients with Low Risk Graft Versus Host Disease
Hematologic
Hematologic
This phase II trial studies how well itacitinib works in treating patients with low risk graft versus host disease. Graft versus host disease is the most common serious complication after bone marrow transplant. It occurs when donor immune cells (the graft) attack normal tissue in the recipient’s body. This inflammatory immune system attack can damage the skin, liver, stomach, and / or intestines. Itacitinib may help reduce the inflammation associated with graft versus host disease by blocking the enzymes associated with activating the inflammatory process.
Hematologic
II
Kitko, Carrie
NCT03846479
VICCPED1912